A Note from ZEISS: Visit us at ARVO 2017; Booth# 3615!
Pravin Dugel, MD
Giuseppe Querques, MD, PhD
Jay Duker, MD
Amir H. Kashani, MD, PhD
Theodore Leng, MD, FACS
David Boyer, MD
David Boyer, MD, discusses the utility of OCT-A for identifying choroidal neovascularization in patients with type 1 AMD and gauging the response to anti-VEGF treatment.
David Boyer MD
David Boyer, MD, presents two cases, highlighting how OCT-A makes it easier to assess response to anti-VEGF treatment and visualize the extent of choroidal neovascularization in eyes with AMD.
Peter Kaiser, MD
Peter Kaiser, MD, discusses practical applications for use of OCT-A among patients with Types 1, 2, and 3 choroidal neovascularization, offering insights on how this modality may shape clinical practice.
Giuseppe Querques, MD, PhD, discusses correlations between OCT-A findings and the classical Gass system for classifying Type 1 AMD.
Pravin Dugel, MD, presents cases in which OCT-A would direct therapy choices that would not otherwise be dictated by conventional retreatment criteria.
Giuseppe Querques, MD, PhD, demonstrates OCT-A segmentation for understanding Type 1 neovascularization.
Giuseppe Querques, MD, PhD, demonstrates OCT-A images depicting hallmark findings associated with type 2 neovascularization.
Giuseppe Querques, MD, PhD, demonstrates how OCT-A may be used to visualize the formation of anastomosis and identify the layers of new vessel growth in eyes with type 3 neovascularization.
Giuseppe Querques, MD, PhD, discusses using OCT-A as a tool to identify treatment-naïve quiescent neovascularization. According to Dr. Querques, understanding distinct morphologic patterns on OCT-A may help guide management decisions.
+ show more
What is the potential value of adding OCT angiography to a busy retinal practice? According to Jay Duker, MD, OCT-A may facilitate changes in clinical workflow by allowing more rapid and less invasive diagnosis, and it may have implications for changing retreatment criteria and for following patients over time.
Jean-Francois Korobelnik, MD
Jean-Francois Korobelnik, MD reviews OCT angiography, including how the technology works, how it may be applied in clinical practice, and what benefits the AngioPlex platform provide for greater understanding of the retinal vasculature.
In this live demonstration, an OCT-A image is captured in real time, demonstrating its ease of use and speed of capture.
Philip Rosenfeld, MD, PhD
Philip Rosenfeld, MD, PhD, presents a case of a patient with uncontrolled diabetic retinopathy treated with anti-VEGF medications and followed with OCT-A. The case highlights that OCT-A may help identify clinical features that may not be readily appreciable on OCT B-scan.
Philip Rosenfeld, MD, PhD, presents a case demonstrating the utility of OCT-A for following NVE and NVD in an eye with diabetic retinopathy. In particular, imaging was useful for guiding the need for retreatment.
In this video, Amir H. Kashani, MD, PhD, describes why diabetic retinopathy may be the perfect model for understanding the potential role of OCT angiography in diagnosing, grading, and managing retinal and macular pathology.
Amir H. Kashani, MD, PhD, shows examples of cases in which OCT-A provided warning signs of active disease.
Amir H. Kashani, MD, PhD, and a panel of experts discuss the evolving role of FA and OCT-A in the management of DR. The panel focuses on how OCT-A may shape management and treatment decision-making.
Thedore Leng, MD, FACS reviews the important differences between OCT-A and FA in eyes with retinal vein occlusion, including how and why OCT-A may display greater detail of the capillaries.
Theodore Leng, MD, and a panel of experts address the question of whether OCT-A should be captured for every patient with retinal vein occlusion.
Thedore Leng, MD, FACS, provides an overview of OCT-A imaging in the management of retinal vein occlusion. According to Dr. Leng, there is strong rationale for the addition of OCT-A for purposes of diagnosing and following patients over the course of treatment.
Jay Duker, MD, presents a case of central serous retinopathy in 47-year-old woman in which OCT-A helped determine the treatment course.
Peter Kaiser, MD, shares the results of a study at his institution demonstrating that OCT-A was superior to fluorescein angiography for the detection of neovascularization in eyes with active uveitis. In particular, OCT-A may be more sensitive for differentiating inflammatory lesions compared with neovascularization.
Francesco Bandello, MD
Francesco Bandello, MD, discusses the use of OCT-A to define characteristics of CNV that would help determine whether patients have inactive versus inactive pathologic myopia.
Thedore Leng, MD, FACS, demonstrates how OCT-A provides insights into the microvascular implications of Stargardt disease—pathology that would be masked by the dye in a fluorescein angiogram. According to Dr. Leng, identifying these pathologic findings may be important if they can be correlated to visual function and prognosis.
Visit us online at zeiss.com/octangio
Learn more about OCT-A at these upcoming events
ADD TO CALENDAR
FOR OUTSIDE US
EN_31_174_0061I / US_31_174_0061I
© 2017 Bryn Mawr Communications, LLC. All Rights Reserved
1008 Upper Gulph Rd, Wayne, PA 19087 | (484) 581-1800